References
- CollacoJMcGreadyJGreenDMEffect of temperature on cystic fibrosis lung disease and infections: a replicated cohort studyPLoS One2011611e2778422125624
- EdelsteinMVSkleenovaENShevchenkoOVSpread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical studyLancet Infect Dis2013131086787623845533
- DaviesJCPseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistencePaediatr Respir Rev20023212813412297059
- MogayzelPJJrNaureckasETRobinsonKACystic fibrosis pulmonary guidelinesAm J Respir Crit Care Med2013187768068923540878
- DöringGFlumePHeijermanHElbornJSConsensus Study GroupTreatment of lung infection in patients with cystic fibrosis: current and future strategiesJ Cyst Fibros201211646147923137712
- SmythARBellSCBojcinSEuropean Cystic Fibrosis Society Standards of Care: best practice guidelinesJ Cyst Fibros201413Suppl 1S23S4224856775
- QuittnerALBuuAEffects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infectionPediatr Pulmonol200233426927611921456
- RamseyBWPepeMSQuanJMIntermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study GroupN Engl J Med1999340123309878641
- MurphyTDAnbarRDLesterLATreatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung diseasePediatr Pulmonol200438431432015334509
- SawickiGSSignorovitchJEZhangJReduced mortality in cystic fibrosis patients treated with tobramycin inhalation solutionPediatr Pulmonol2012471445221815282
- KonstanMWGellerDEMinićPBrockhausFZhangJAngyalosiGTobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trialPediatr Pulmonol201146323023820963831
- KonstanMWFlumePAKapplerMSafety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trialJ Cyst Fibros2011101546121075062
- HarrisonMJMcCarthyMFlemingCInhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF)J Cyst Fibros201413669269824815094
- GellerDEKonstanMWSmithJNoonbergSBConradCNovel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safetyPediatr Pulmonol200742430731317352404
- VandevanterDRGellerDETobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a reviewMed Devices (Auckl)2011417918822915944
- HarrisPATaylorRThielkeRPayneJGonzalezNCondeJGResearch electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics supportJ Biomed Inform200942237738118929686
- AtkinsonMJSinhaAHassSLValidation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth Qual Life Outcomes200421214987333
- RegnaultABalpMMKulichKViala-DantenMValidation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosisJ Cyst Fibros201211649450122583743
- QuittnerABuuAMesserMAModiACWatrousMDevelopment and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosisChest200512842347235416236893
- SawickiGSSellersDERobinsonWMAssociations between illness perceptions and health-related quality of life in adults with cystic fibrosisPsychosom Res2011702161167
- ZiaianTSawyerMGReynoldsKETreatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthmaJ Paediatr Child Health2006421059660016972965
- SawickiGSSellersDERobinsonWMHigh treatment burden in adults with cystic fibrosis: challenges to disease self-managementJ Cyst Fibros200982919618952504